<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)</h1>

    <table>
      <tr><th>Ticker</th><td>MBRX</td></tr>
      <tr><th>Float</th><td>3.0 M</td></tr>
      <tr><th>IO</th><td>2.61%</td></tr>
      <tr><th>MC</th><td>14.0 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Moleculin Biotech (NASDAQ: MBRX) reported preliminary blinded efficacy from its Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine in relapsed/refractory AML: a composite complete remission rate (CRc) of 40% among the first 30 subjects (CR 30%, CRh 10%). The company has treated 35 subjects to date with ~11 more identified and is targeting treatment of 45 subjects in Q1 2026, followed by unblinding (expected late Q2 2026 after data lock). The randomized, double-blind, placebo-controlled adaptive Part A will compare two Annamycin dosing arms plus cytarabine versus cytarabine plus placebo; the first unblinding should include ~30 Annamycin subjects and ~15 control subjects. Company highlights: ~35% of treated subjects are prior venetoclax regimen failures, absence of observed cardiotoxicity in prior trials (90 subjects), Fast Track and Orphan Drug designations, and composition-of-matter patent protection through 2040 (potential extension to 2045). The release notes the data are preliminary/blinded and subject to audit and lock, recruitment challenges, and that the company will require significant additional financing.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Preliminary blinded CRc of 40% in first 30 subjects (CR 30%, CRh 10%)</li><li>35 subjects treated to date; targeting 45 treated in Q1 2026 for first unblinding</li><li>Trial is randomized, double-blind, placebo-controlled adaptive Phase 2B/3</li><li>Approximately 35% of subjects are venetoclax regimen failures (difficult-to-treat population)</li><li>Prior safety data from 90 subjects show continued absence of cardiotoxicity</li><li>Annamycin has FDA Fast Track Status and Orphan Drug designations; patent protection through 2040 (potential to 2045)</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Data are preliminary and blinded and may differ from final locked results</li><li>Early sample size is small (n=30 for reported CRc; 35 treated overall)</li><li>Blinded dataset includes control arm subjects (company estimates ~1/3 may not have received Annamycin)</li><li>Recruitment challenges: higher-than-expected disqualification rate due to prior therapies</li><li>Company states it will require significant additional financing with no commitments</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/a7b75aea-5a16-4cf8-aac0-e6b0e8315b52" target="_blank">Original Article</a>
    </div>

    <div class="small">MBRX â€¢ TradersLink AI News</div>
  </div>
</body>
</html>